Lipocine Inc. (NASDAQ: LPCN) announced that one-third of planned patients have been randomized in its Phase 3 clinical trial evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE